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Vaccination for viral diseases has markedly reduced mortality worldwide for more than 200 years. The greatest 
public health success can be attributed to vaccination. Nevertheless, the future is abound with challenges as there 
remains many diseases that do not yet have effective vaccines against diseases such as HIV/AIDS, myocarditis 
caused by Coxsackievirus B3, Type I diabetes associated with Coxsackievirus B4 and the Hand, Foot, Mouth 
(HFMD) disease caused by Enterovirus 71. Although there are more vaccines undergoing clinical trials, it is 
worrying to note that humans remain vulnerable to the existing 180 or so viruses that have no effective vaccines. 
Therefore, further research is required in the development of new and better vaccines. Of increasing interest in 
recent years would be the design of novel live attenuated vaccines (LAV). This type of vaccine does not require 
cold-chain, is cheaper to produce, induces excellent immunogenicity, does not need boosters and confers live-
long immunity.  With a growing understanding of the molecular basis of virulence in diseases, safe and effective 
LAVs can be developed through optimization of immunogenicity and genetic stability. In this paper, attenuation 
of virulence for viruses causing diseases such as poliomyelitis, HFMD, myocarditis and diabetes type I are 
examined. 
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